Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

References

• Centers for Disease Control and Prevention National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005 US Department of Health and Human Services, Centers for Disease Control and Prevention 2005 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf Accessed May 12, 2013
   Google Scholar
• Klein R Klein BE Moss SE Davis MD DeMets DL The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 1984 102 4 527 532 6367725
   PubMed Web of Science ®Google Scholar
• Tranos PG Wickremasinghe SS Stangos NT Topouzis F Tsinopoulos I Pavesio CE Macular edema Surv Ophthalmol 2004 49 5 470 490 15325193
   PubMed Web of Science ®Google Scholar
• Gardner TW Sander B Larsen ML An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial Curr Eye Res 2006 31 6 535 547 16769613
   PubMed Web of Science ®Google Scholar
• Klein R Knudtson MD Lee KE Gangnon R Klein BE The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes Ophthalmology 2009 116 3 497 503 19167079
   PubMed Web of Science ®Google Scholar
• Ferris FL3rd Patz A Macular edema. A complication of diabetic retinopathy Surv Ophthalmol 1984 28 Suppl S452 S461
   PubMed Web of Science ®Google Scholar
• Yau JW Rogers SL Kawasaki R Meta-Analysis for Eye Disease (META-EYE) Study Group Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 2012 35 3 556 564 22301125
   PubMed Web of Science ®Google Scholar
• Stitt AW Li YM Gardiner TA Bucala R Archer DB Vlassara H Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats Am J Pathol 1997 150 2 523 531 9033268
   PubMed Web of Science ®Google Scholar
• Witmer AN Vrensen GF Van Noorden CJ Schlingemann RO Vascular endothelial growth factors and angiogenesis in eye disease Prog Retin Eye Res 2003 22 1 1 29 12597922
   PubMed Web of Science ®Google Scholar
• Miyamoto K Ogura Y Pathogenetic potential of leukocytes in diabetic retinopathy Semin Ophthalmol 1999 14 4 233 239 10758224
   PubMedGoogle Scholar
• Joussen AM Murata T Tsujikawa A Kirchhof B Bursell SE Adamis AP Leukocyte-mediated endothelial cell injury and death in the diabetic retina Am J Pathol 2001 158 1 147 152 11141487
   PubMed Web of Science ®Google Scholar
• Antonetti DA Barber AJ Hollinger LA Wolpert EB Gardner TW Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors J Biol Chem 1999 274 33 23463 23467 10438525
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 Erratum in: Lancet. 1999;354(9178):602 9742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 1998 317 7160 703 713 9732337
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 1985 103 12 1796 1806 2866759
   PubMedGoogle Scholar
• Mitchell P Bandello F Schmidt-Erfurth U RESTORE study group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 2011 118 4 615 625 21459215
   PubMed Web of Science ®Google Scholar
• Wilson CA Berkowitz BA Sato Y Ando N Handa JT de Juan EJr Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation Arch Ophthalmol 1992 110 8 1155 1159 1497531
   PubMedGoogle Scholar
• Martidis A Duker JS Greenberg PB Intravitreal triamcinolone for refractory diabetic macular edema Ophthalmology 2002 109 5 920 927 11986098
   PubMed Web of Science ®Google Scholar
• Gillies MC Sutter FK Simpson JM Larsson J Ali H Zhu M Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial Ophthalmology 2006 113 9 1533 1538 16828501
   PubMed Web of Science ®Google Scholar
• Jonas JB Kreissig I Söfker A Degenring RF Intravitreal injection of triamcinolone for diffuse diabetic macular edema Arch Ophthalmol 2003 121 1 57 61 12523885
   PubMed Web of Science ®Google Scholar
• Lam DS Chan CK Mohamed S A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema Br J Ophthalmol 2007 91 2 199 203 16973659
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Ophthalmology 2008 115 9 1447 1449 18662829
   PubMed Web of Science ®Google Scholar
• Kim JE Pollack JS Miller DG Mittra RA Spaide RF Isis Study Group ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema Retina 2008 28 5 735 740 18463518
   PubMed Web of Science ®Google Scholar
• Grover D Li TJ Chong CC Intravitreal steroids for macular edema in diabetes [review] Cochrane Database Syst Rev 2008 1 CD005656 18254088
   PubMed Web of Science ®Google Scholar
• Steijns D Duijvesz D Breedijk MA van der Heijden GJ Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review Acta Ophthalmol 2010 88 4 389 393 20222888
   PubMed Web of Science ®Google Scholar
• Kwak HW D’Amico DJ Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection Arch Ophthalmol 1992 110 2 259 266 1736876
   PubMed Web of Science ®Google Scholar
• Scholes GN O’Brien WJ Abrams GW Kubicek MF Clearance of triamcinolone from vitreous Arch Ophthalmol 1985 103 10 1567 1569 4051860
   PubMed Web of Science ®Google Scholar
• Kuppermann BD Blumenkranz MS Haller JA Dexamethasone DDS Phase II Study Group Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema Arch Ophthalmol 2007 125 3 309 317 17353400
   PubMed Web of Science ®Google Scholar
• Haller JA Kuppermann BD Blumenkranz MS Dexamethasone DDS Phase II Study Group Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema Arch Ophthalmol 2010 128 3 289 296 20212197
   PubMed Web of Science ®Google Scholar
• Aiello LP Angiogenic pathways in diabetic retinopathy N Engl J Med 2000 353 8 839 841 16120866
   PubMed Web of Science ®Google Scholar
• Cunningham ETJr Adamis AP Altaweel M Macugen Diabetic Retinopathy Study Group A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 2005 112 10 1747 1757 16154196
   PubMed Web of Science ®Google Scholar
• Arevalo JF Fromow-Guerra J Quiroz-Mercado H Pan-American Collaborative Retina Study Group Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology 2007 114 4 743 750 17398322
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network Scott IU Edwards AR Beck RW A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 2007 114 10 1860 1867 17698196
   PubMed Web of Science ®Google Scholar
• Soheilian M Ramezani A Bijanzadeh B Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema Retina 2007 27 9 1187 1195 18046223
   PubMed Web of Science ®Google Scholar
• Faghihi H Roohipoor R Mohammadi SF Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema Eur J Ophthalmol 2008 18 6 941 948 18988166
   PubMed Web of Science ®Google Scholar
• Nguyen QD Brown DM Marcus DM RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 2012 119 4 789 801 22330964
   PubMed Web of Science ®Google Scholar
• Massin P Bandello F Garweg JG Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 2010 33 11 2399 2405 20980427
   PubMed Web of Science ®Google Scholar
• Nguyen QD Shah SM Khwaja AA READ-2 Study Group Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study Ophthalmology 2010 117 11 2146 2151 20855114
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network Elman MJ Aiello LP Beck RW Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 2010 117 6 1064 1077 20427088
   PubMed Web of Science ®Google Scholar
• Rajendram R Fraser-Bell S Kaines A A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 2012 130 8 972 979 22491395
   PubMed Web of Science ®Google Scholar
• Arevalo JF Lasave AF Wu L Pan-American Collaborative Retina Study Group (PACORES) Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 Months Retina 2013 33 2 403 413 23222389
   PubMed Web of Science ®Google Scholar
• Do DV Nguyen QD Boyer D DA VINCI Study Group One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 2012 119 8 1658 1665 22537617
   PubMed Web of Science ®Google Scholar
• van der Reis MI La Heij EC De Jong-Hesse Y Ringens PJ Hendrikse F Schouten JS A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections Retina 2011 31 8 1449 1469 21817960
   PubMed Web of Science ®Google Scholar
• Virgili G Parravano M Menchini F Brunetti M Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema [review] Cochrane Database Syst Rev 2012 12 CD007419 23235642
   PubMed Web of Science ®Google Scholar
• Nasrallah FP Jalkh AE Van Coppenolle F The role of the vitreous in diabetic macular edema Ophthalmology 1988 95 10 1335 1339 3226682
   PubMed Web of Science ®Google Scholar
• Lewis H Abrams GW Blumenkranz MS Campo RV Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction Ophthalmology 1992 99 5 753 759 1594222
   PubMed Web of Science ®Google Scholar
• Pendergast SD Hassan TS Williams GA Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid Am J Ophthalmol 2000 130 2 178 186 11004291
   PubMed Web of Science ®Google Scholar
• Harbour JW Smiddy WE Flynn HWJr Rubsamen PE Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane Am J Ophthalmol 1996 121 4 405 413 8604734
   PubMed Web of Science ®Google Scholar
• Ikeda T Sato K Katano T Hayashi Y Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes Br J Ophthalmol 1999 83 1 12 14 10209427
   PubMed Web of Science ®Google Scholar
• Yanyali A Horozoglu F Celik E Nohutcu AF Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema Retina 2007 27 5 557 566 17558316
   PubMed Web of Science ®Google Scholar
• Dillinger P Mester U Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema Graefes Arch Clin Exp Ophthalmol 2004 242 8 630 637 15221304
   PubMed Web of Science ®Google Scholar
• Kumagai K Furukawa M Ogino N Larson E Iwaki M Tachi N Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema Retina 2009 29 4 464 472 19289987
   PubMed Web of Science ®Google Scholar
• Flaxel CJ Edwards AR Aiello LP Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network Retina 2010 30 9 1488 1495 20924264
   PubMed Web of Science ®Google Scholar
• Taylor SR Isa H Joshi L Lightman S New developments in corticosteroid therapy for uveitis Ophthalmologica 2010 224 Suppl 1 S46 S53
   PubMed Web of Science ®Google Scholar
• Fluocinolone acetonide ophthalmic–Bausch and Lomb: fluocinolone actinide Envision TD implant Drugs R D 2005 6 2 116 119 15777105
   PubMedGoogle Scholar
• Pearson PA Comstock TL Ip M Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial Ophthalmology 2011 118 8 1580 1587 21813090
   PubMed Web of Science ®Google Scholar
• Pearson PA Levy B Comstock T Fluocinolone Acetonide Implant Study Group Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: a 3–year results of a multi–center clinical trial Invest Ophthalmol Vis Sci 2006 47 E-Abstract 5442
   Google Scholar
• Campochiaro PA Hafiz G Shah SM Famous Study Group Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert Ophthalmology 2010 117 7 1393 1399 20202684
   PubMed Web of Science ®Google Scholar
• Campochiaro PA Brown DM Pearson A FAME Study Group Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 2011 118 4 626 635 21459216
   PubMed Web of Science ®Google Scholar
• Campochiaro PA Brown DM Pearson A FAME Study Group Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema Ophthalmology 2012 119 10 2125 2132 22727177
   PubMed Web of Science ®Google Scholar